EP1162963A1 - Means for diagnosing and treating carcinoma - Google Patents

Means for diagnosing and treating carcinoma

Info

Publication number
EP1162963A1
EP1162963A1 EP00912602A EP00912602A EP1162963A1 EP 1162963 A1 EP1162963 A1 EP 1162963A1 EP 00912602 A EP00912602 A EP 00912602A EP 00912602 A EP00912602 A EP 00912602A EP 1162963 A1 EP1162963 A1 EP 1162963A1
Authority
EP
European Patent Office
Prior art keywords
hypericin
preparation
carcinoma
instillation
bladder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00912602A
Other languages
German (de)
French (fr)
Inventor
Peter Alfred Maria De Witte
Etienne Jean Pierre Marie Waelkens
Marie-Ange D'hallewin
Luc Baert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Katholieke Universiteit Leuven
Original Assignee
Katholieke Universiteit Leuven
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Katholieke Universiteit Leuven filed Critical Katholieke Universiteit Leuven
Priority to EP00912602A priority Critical patent/EP1162963A1/en
Publication of EP1162963A1 publication Critical patent/EP1162963A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to the diagnosis and treatment of carcinoma, in particular of carcinoma of hollow organs, such as the urinary tract, including the bladder, bronchi, peritoneal cavity, gastrointestinal tract, female genital tract.
  • carcinoma in particular of carcinoma of hollow organs, such as the urinary tract, including the bladder, bronchi, peritoneal cavity, gastrointestinal tract, female genital tract.
  • the invention relates in particular to diagnosis and treatment of carcinoma of the urothelium with a special interest of carcinoma of the bladder.
  • Bladder cancer is the sixth most common malignant disease worldwide. When first diagnosed, 75 to 85% of the patients have superficial tumors. More than 70% of patients with superficial bladder tumors will have one or more recurrences after initial therapy and in about one third tumor progression is observed. The cause for this high recurrence rate is the fact that small papular lesions can be overlooked. Progression is mostly due to the presence of flat carcinoma in situ.
  • Carcinoma in situ (CIS) of the bladder is a confounding disease that is difficult to recognize clinically as well as histopathologically. Many studies have suggested its relationship with subsequent invasive disease.
  • a study of natural history of untreated CIS has been reported by Wolf et al . (Wolf et al . , Scand. J. Urol. Nephrol. Suppl . 157:147-151 (1994)).
  • CIS Carcinoma in situ
  • the object of the invention to provide a new way of diagnosing carcinoma in general, carcinoma of hollow organs in particular and of the urothelium more in particular and specifically CIS without the drawbacks of the known methods described above .
  • hypericin as a diagnostic or therapeutic agent.
  • analogues or derivatives thereof can be used.
  • Such analogues or derivatives contain modifications that are intended to modify the solubility or other physical parameters of the hypericin, but are not intended to change the fluorescent nature of hypericin. This means that for example hypericin polyacetate and hypericin polyphosphate, derivatives that are no longer fluorescent per se, are excluded for the use of the invention.
  • Hypericin is the hexahydroxydimethyl derivative of phenantroperylene dione and is one of the major photosensitizing constituents present in Hypericum extracts.
  • the extract of Hypericum is used in the treatment of mild to moderately depressive disorders, especially in German speaking countries. Hypericin shows a bright red fluorescence when excited.
  • the photodynamic characteristics of the compound on human cell lines have been shown in vitro (Hadjur et al . , J. Photochem. Photobiol . B. Biol . 27, 139-146 (1995); Canwell et al . , Neurosurgery 35, 705-709 (1994); Zhang et al . , Neurosurgery 38, 705-709 (1996); Zhang et al .
  • Vandenbogaerde et al . (Anticancer Res. 16, 1619-1626 (1996) ) reported the selective accumulation and antitumoral activity of photosensitized hypericin in A431 cell xenografts in athymic nude mice. The accumulation in the tumor in this case took place after hypericin was illuminated.
  • hypericin exhibited in vitro a differential phototoxicity against several human tumor cell lines depending on the uptake of the compound by the cells (Vandenbogaerde et al . , J. Photochem. Photobiol. B. 38, 136-142 (1997)).
  • hypericin topically as photochemotherapeutic agent in squamous cell and basal cell carcinoma (Alecu et al . , Anticancer Res. 18, 4651-4654 (1998)). For this hypericin was injected into the tumor and illuminated afterwards.
  • Hypericin derivatives have been used for diagnosis of tumors.
  • WO97/03697 for example describes that tumor cells contain enzymes that convert non- fluorescent compounds, such as hypericin polyacetate or hypericin polyphosphate, into fluorescent compounds.
  • Non- tumor cells do not contain the same (amount) of enzymes. Tumor cells are thus preferentially stained because they can convert the substrate into a fluorescent form.
  • the present invention does not rely on a fluorogenic compound, but starts out with hypericin per se, which is already fluorescent, and which is now surprisingly found to preferentially accumulate in the tumor tissues.
  • W094/14956 relates to the use of an energy donating chemical together with a photosensitizing chemical, such as hypericin or porphyrin.
  • the energy donating chemical is used as a molecular flashlight to photoactivate the photosensitizing chemical and is in turn activated by an activating chemical.
  • the activating chemical must be regulated such that activation occurs solely in tumor cells. For this additional, rather complicated methods are needed.
  • the present invention relies solely on the direct activation of hypericin by light and its specificity is based on the surprising finding that tumor cells preferentially accumulate hypericin.
  • the present inventors were the first to identify hypericin as a selective tumor marker, in particular for bladder cancer. Surprisingly, it was found that hypericin was capable of concentrating very specifically into the tumor. Except for the tumor no other tissues showed fluorescence after illumination thus demonstrating the specificity. The advantage of this is that the amount of false positives will be lower than with the known markers, such as ALA.
  • the diagnostic method and treatment of the invention can be applied to various hollow organs, such as the urinary tract, including the bladder, bronchi, peritoneal cavity, gastrointestinal tract, female genital tract .
  • urinary tract including the bladder, bronchi, peritoneal cavity, gastrointestinal tract, female genital tract .
  • the diagnostic or therapeutic preparation can take the form of an inhaler and the diagnosis or therapy can be made through endoscopy.
  • peritoneal cavity laparoscopy is a suitable technique for applying the preparation and for illumination thereof and observation of the fluorscence.
  • the preparation can be taken orally.
  • oesophagus When the oesophagus is to be diagnosed or treated use can be made of two balloons that close of the oesophagus and in between which the fluid can be kept for a certain period of time. Diagnosis and treatment can again be made through endoscopy.
  • a diagnostic preparation of the invention comprises hypericin and a suitable carrier or excipient and preferably takes the form of an instillation fluid.
  • the instillation fluid is brought into the bladder and left there for a predetermined period of time. After removal of the fluid, the bladder can be illuminated with light that excites hypericin, e.g. blue light.
  • the hypericin that is accumulated in the bladder carcinoma When excited the hypericin that is accumulated in the bladder carcinoma will emit orange-red fluorescence of 600-640 nm. This fluorescence can be detected with slightly modified lenses to enhance the blue/red contrast.
  • diagnosis can be coupled to local treatment by longer illumination times . Because the specificity of hypericin is so high, the treatment can also be highly specific and localised to the actual place of the tumor. Treatment without direct preceding diagnosis is also part of the invention. In that case, a higher total light dose should be used, reaching typically 15 J/cm 2 (unscattered) .
  • hypericin is admixed with inter alia a plasma protein solution.
  • a preparation that is obtainable by dissolving hypericin in PEG 400 and subsequently diluting the thus obtained solution with an aqueous buffer of bladder-compatible pH, containing mannitol, sorbitol or other poly-alcohols.
  • the thus obtained concentrated preparation is stable and can be diluted in a desired buffer solution.
  • a lyophilized preparation of buffer, additives and hypericin may be used, which is reconstituted with water prior to use.
  • Example 1 will show that hypericin has various advantages over the commonly used ALA.
  • the use of hypericin for diagnosis according to the invention leads to a specificity in case of instillations of 98% with a negative predictive value (probability of a patient not having the disease when the test is negative) of 91%.
  • the sensitivity after hypericin instillations is comparable to ALA.
  • Hypericin induced by ALA is rapidly bleached out and exposure to blue light has to be limited to short illumination periods in order to inspect the whole bladder.
  • Hypericin induced fluorescence on the contrary is very stable, and the bladder can be fully inspected during the whole procedure .
  • Another advantage of hypericin as compared to ALA is the very slow fluorescence decay as a result of which patients can be instilled up to 16 hours prior to endoscopic inspection.
  • hypericin can be used in lower concentrations than are used for other applications such as the treatment of depression or phytotoxicity .
  • the amount to be administered for diagnosis according to the invention is about a tenfold lower than the oral dose of total hypericin used to treat depression and approximately a 100 times lower than the phototoxic dose after oral administration of the Hypericum extract .
  • an instillation solution for example plasma proteins in an isotonic buffered solution (pH 7.4)
  • an instillation solution for example plasma proteins in an isotonic buffered solution (pH 7.4)
  • the total amount of hypericin instilled lies between 25 and 250 ⁇ g. Higher concentrations lead to loss of specificity wheras no fluorescence is detected when lower concentrations are used.
  • Hypericin is a lipophilic molecule and will therefore not readily dissolve in an aqueous medium.
  • hypericin is preferably adsorbed to a protein, in particular albumin or a plasma protein preparation for solubilisation.
  • a protein in particular albumin or a plasma protein preparation for solubilisation.
  • solubilisation means such as cyclodextrin or liposomes.
  • Hypericin (as salt) for use in the invention can be either isolated from Hypericum species (e.g. H.perforatum) or synthetically prepared.
  • hypericin as used in this application is intended to encompass hypericin (as salt) itself, but also modified versions (analogues) or derivatives thereof.
  • a preferred modification is a modification that leads to a higher hydrophilicity, thus facilitating dissolution of the compound in an aqueous medium.
  • Such modifications can be formation of ethers or esters on the phenols or substitution of the aromatic rings .
  • the instillation solution was prepared as follows. 1 to 10 mM hypericin in absolute ethanol was diluted a thousand fold in a 1% plasma protein solution and sterile membrane filtered. 29 patients were included in the study. 22 presented with visible exophytic transitional cell carcinoma. One patient had interstitial cystitis. 7 patients had repeated positive urinary cytology, without detectable lesions at cystoscopy, sonography or urogram. Random biopsies previously performed without hypericin instillation had been negative in 2 of them.
  • Instillation time varied between 1 and 4 hours (1, 2, 3 and 4 hours) .
  • the system used for fluorescence diagnostics was developed by Storz company (D Light system) . It consists of a small light source, with a Xenon arc lamp with a corresponding band pass filter (380-450 nm) . By switching the foot pedal, the filter is placed or removed and blue or white light is produced, respectively.
  • a conventional cystoscope is used for endoscopic examination, but the telescopes (0° and 30°) are provided with a long wavelength pass filter (>520 nm) to cut off the reflected blue excitation light without blocking the red fluorescence light.
  • the telescopes are compatible with all Storz endoscopes .
  • Biopsies were performed from fluorescent positive and negative areas. The instillation did not provoke any side effects nor symptoms.
  • Carcinoma in situ could be correctly diagnosed in all of the patients with a suspicious cytology, without detectable tumor.
  • 66 biopsies confirmed the presence of carcinoma in situ (Table 1) . 56 of those biopsies had shown red fluorescence at cystoscopy.
  • the sensitivity is the chance that the test will give a positive result in case a pathology is present and is obtained by dividing the amount of exact positives by the total of exact positives and false negatives.
  • the specificity is the chance that a malignancy is present when the test is positive and is obtained by dividing exact negative by the sum of exact negatives and false positives .
  • a concentrated preparation for installation was prepared as follows. Hypericin was dissolved in PEG 400 to a final concentration of 5 mM. The thus obtained solution is further diluted while stirring to 80 ⁇ M in an aqueous phosphate buffer, containing 4.2% mannitol (pH
  • the content of the vials can be added to 45 ml of an aqueous buffer of choice.
  • the final concentration of the 50 ml installation fluid thus obtained is 8 ⁇ M.
  • the concentrate was kept in the dark at room temperature for 1 month before use. Its diagnostic potential was then found to be identical to preparations containing a plasma protein solution.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to the use of hypericin or analogues or derivatives thereof for the preparation of a diagnostic composition for diagnosing carcinoma, more in particular carcinoma originating from urothelium, especially carcinoma of the bladder. In addition the invention provides an installation fluid comprising hypericin or analogues or derivatives thereof for use in a method for diagnosing such carcinomas.

Description

MEANS FOR DIAGNOSING AND TREATING CARCINOMA
The present invention relates to the diagnosis and treatment of carcinoma, in particular of carcinoma of hollow organs, such as the urinary tract, including the bladder, bronchi, peritoneal cavity, gastrointestinal tract, female genital tract. The invention relates in particular to diagnosis and treatment of carcinoma of the urothelium with a special interest of carcinoma of the bladder.
Cancer is one of the most common causes of death in the world. Bladder cancer is the sixth most common malignant disease worldwide. When first diagnosed, 75 to 85% of the patients have superficial tumors. More than 70% of patients with superficial bladder tumors will have one or more recurrences after initial therapy and in about one third tumor progression is observed. The cause for this high recurrence rate is the fact that small papular lesions can be overlooked. Progression is mostly due to the presence of flat carcinoma in situ.
Carcinoma in situ (CIS) of the bladder is a confounding disease that is difficult to recognize clinically as well as histopathologically. Many studies have suggested its relationship with subsequent invasive disease. A study of natural history of untreated CIS has been reported by Wolf et al . (Wolf et al . , Scand. J. Urol. Nephrol. Suppl . 157:147-151 (1994)). Of the 31 study patients with a mean follow up of more than 5 years, 52% had tumor progression to invasive disease and 48% has stable disease. Only 3 from the patients with stable disease had no tumor recurrence during follow up. Early recognition of carcinoma in situ is essential in order to offer the patients the most appropriate treatment and the highest cure rate. Since white light cystoscopic examination is not sufficient to reveal areas of dysplasia or carcinoma in situ, random biopsies are recommended. Attempts have been made to develop various methods for in vivo labeling of those early cancers. Intravesical instillations of methylene blue have been abandoned because of the high rate of false negative results (70 to 85%) .
Previously the detection of carcinoma in situ and dysplasia after Photofrin systemic injections was described. Disadvantages of this technique however are skin photosensitization for 24 hours, the requirement of administration of the drug 48 hours prior to the investigation, the point monitoring system that limits the detection area to 600 μm at a time and the diagnostic equipment itself, which must be handled by a physicist. Aminolevulinic acid (ALA) is another photosensitizer that can be used to tag bladder tumors. ALA can be administered intravesically, thereby eliminating systemic side effects. First reports were presented by Kriegmair et al . (J. Urol. 155, 105-109 (1996) ) . Six areas of carcinoma in situ were correctly diagnosed but 80% of false positive fluorescence areas were observed. More recently, Jichlinski et al . (Urol. Res. 25 suppl. 1, 3-6 (1997)) reported with the same technique a sensitivity and specificity to detect CIS of 83% and 81%, respectively. However, using exactly the same method, D'Hallewin et al . (Am. Clin. J. Oncol.
21(3), 223-225 (1998)) were not able to reproduce these data. The sensitivity to detect CIS was 94% but with a specificity of only 54%.
With the currently used fluorescence diagnostic techniques, the sensitivity to detect CIS is much higher than with the naked eye, but the relative lack of specificity is responsible for a high amount of false positive results.
In view of the above it is the object of the invention to provide a new way of diagnosing carcinoma in general, carcinoma of hollow organs in particular and of the urothelium more in particular and specifically CIS without the drawbacks of the known methods described above .
This is achieved according to the invention by using hypericin as a diagnostic or therapeutic agent. Instead of or in addition to hypericin per se analogues or derivatives thereof can be used. Such analogues or derivatives contain modifications that are intended to modify the solubility or other physical parameters of the hypericin, but are not intended to change the fluorescent nature of hypericin. This means that for example hypericin polyacetate and hypericin polyphosphate, derivatives that are no longer fluorescent per se, are excluded for the use of the invention.
Hypericin is the hexahydroxydimethyl derivative of phenantroperylene dione and is one of the major photosensitizing constituents present in Hypericum extracts. The extract of Hypericum is used in the treatment of mild to moderately depressive disorders, especially in German speaking countries. Hypericin shows a bright red fluorescence when excited. The photodynamic characteristics of the compound on human cell lines have been shown in vitro (Hadjur et al . , J. Photochem. Photobiol . B. Biol . 27, 139-146 (1995); Couldwell et al . , Neurosurgery 35, 705-709 (1994); Zhang et al . , Neurosurgery 38, 705-709 (1996); Zhang et al . , Cancer Lett. 96, 31-35 (1995); and VanderWerf et al . , Laryngoscope 106, 479-483 (1996)). Vandenbogaerde et al . (Anticancer Res. 16, 1619-1626 (1996) ) reported the selective accumulation and antitumoral activity of photosensitized hypericin in A431 cell xenografts in athymic nude mice. The accumulation in the tumor in this case took place after hypericin was illuminated.
In addition, it was demonstrated that hypericin exhibited in vitro a differential phototoxicity against several human tumor cell lines depending on the uptake of the compound by the cells (Vandenbogaerde et al . , J. Photochem. Photobiol. B. 38, 136-142 (1997)). Recently a first clinical study was published using hypericin topically as photochemotherapeutic agent in squamous cell and basal cell carcinoma (Alecu et al . , Anticancer Res. 18, 4651-4654 (1998)). For this hypericin was injected into the tumor and illuminated afterwards.
Hypericin derivatives have been used for diagnosis of tumors. WO97/03697 for example describes that tumor cells contain enzymes that convert non- fluorescent compounds, such as hypericin polyacetate or hypericin polyphosphate, into fluorescent compounds. Non- tumor cells do not contain the same (amount) of enzymes. Tumor cells are thus preferentially stained because they can convert the substrate into a fluorescent form. The present invention does not rely on a fluorogenic compound, but starts out with hypericin per se, which is already fluorescent, and which is now surprisingly found to preferentially accumulate in the tumor tissues.
W094/14956 relates to the use of an energy donating chemical together with a photosensitizing chemical, such as hypericin or porphyrin. The energy donating chemical is used as a molecular flashlight to photoactivate the photosensitizing chemical and is in turn activated by an activating chemical. The activating chemical must be regulated such that activation occurs solely in tumor cells. For this additional, rather complicated methods are needed. The present invention relies solely on the direct activation of hypericin by light and its specificity is based on the surprising finding that tumor cells preferentially accumulate hypericin.
The present inventors were the first to identify hypericin as a selective tumor marker, in particular for bladder cancer. Surprisingly, it was found that hypericin was capable of concentrating very specifically into the tumor. Except for the tumor no other tissues showed fluorescence after illumination thus demonstrating the specificity. The advantage of this is that the amount of false positives will be lower than with the known markers, such as ALA.
The diagnostic method and treatment of the invention can be applied to various hollow organs, such as the urinary tract, including the bladder, bronchi, peritoneal cavity, gastrointestinal tract, female genital tract . For diagnosis of the urinary and genital tracts use can be made of instillation fluids. For the bronchi the diagnostic or therapeutic preparation can take the form of an inhaler and the diagnosis or therapy can be made through endoscopy. In the case of the peritoneal cavity laparoscopy is a suitable technique for applying the preparation and for illumination thereof and observation of the fluorscence. For the gastroinstestinal tract the preparation can be taken orally. When the oesophagus is to be diagnosed or treated use can be made of two balloons that close of the oesophagus and in between which the fluid can be kept for a certain period of time. Diagnosis and treatment can again be made through endoscopy.
A diagnostic preparation of the invention comprises hypericin and a suitable carrier or excipient and preferably takes the form of an instillation fluid. The instillation fluid is brought into the bladder and left there for a predetermined period of time. After removal of the fluid, the bladder can be illuminated with light that excites hypericin, e.g. blue light.
When excited the hypericin that is accumulated in the bladder carcinoma will emit orange-red fluorescence of 600-640 nm. This fluorescence can be detected with slightly modified lenses to enhance the blue/red contrast.
If desired the diagnosis can be coupled to local treatment by longer illumination times . Because the specificity of hypericin is so high, the treatment can also be highly specific and localised to the actual place of the tumor. Treatment without direct preceding diagnosis is also part of the invention. In that case, a higher total light dose should be used, reaching typically 15 J/cm2 (unscattered) .
Usually hypericin is admixed with inter alia a plasma protein solution. However, because of the risks that may be associated with the use of plasma products it would be desirable to have a preparation free of such plasma derived products. This is achieved by the present invention by a preparation that is obtainable by dissolving hypericin in PEG 400 and subsequently diluting the thus obtained solution with an aqueous buffer of bladder-compatible pH, containing mannitol, sorbitol or other poly-alcohols. The thus obtained concentrated preparation is stable and can be diluted in a desired buffer solution. As an alternative, a lyophilized preparation of buffer, additives and hypericin may be used, which is reconstituted with water prior to use.
Example 1 will show that hypericin has various advantages over the commonly used ALA. In a study with 29 patients it was found that the use of hypericin for diagnosis according to the invention leads to a specificity in case of instillations of 98% with a negative predictive value (probability of a patient not having the disease when the test is negative) of 91%. The sensitivity after hypericin instillations is comparable to ALA.
It is interesting to note that in 7 out of the 10 false negative CIS biopsies, severe desquamation was noted, with only a few cells remaining to make the diagnosis. Diagnosis with ALA results in bright fluorescence in severely infectious eroded areas, as well as in case of desquamated CIS.
Fluorescence induced by ALA is rapidly bleached out and exposure to blue light has to be limited to short illumination periods in order to inspect the whole bladder. Hypericin induced fluorescence on the contrary is very stable, and the bladder can be fully inspected during the whole procedure . Another advantage of hypericin as compared to ALA is the very slow fluorescence decay as a result of which patients can be instilled up to 16 hours prior to endoscopic inspection. According to the invention hypericin can be used in lower concentrations than are used for other applications such as the treatment of depression or phytotoxicity . Typically, the amount to be administered for diagnosis according to the invention, is about a tenfold lower than the oral dose of total hypericin used to treat depression and approximately a 100 times lower than the phototoxic dose after oral administration of the Hypericum extract .
According to the invention it is advised to use 25 to 100 ml, preferably 50 ml of an instillation solution (for example plasma proteins in an isotonic buffered solution (pH 7.4)) which will be instilled for 2 to 4 hours, preferably 2 hours with a hypericin concentration of 1 to 10 μM. The total amount of hypericin instilled lies between 25 and 250 μg. Higher concentrations lead to loss of specificity wheras no fluorescence is detected when lower concentrations are used.
Hypericin is a lipophilic molecule and will therefore not readily dissolve in an aqueous medium.
Therefore hypericin is preferably adsorbed to a protein, in particular albumin or a plasma protein preparation for solubilisation. In addition other solubilisation means can be used, such as cyclodextrin or liposomes. Hypericin (as salt) for use in the invention can be either isolated from Hypericum species (e.g. H.perforatum) or synthetically prepared.
The term "hypericin" as used in this application is intended to encompass hypericin (as salt) itself, but also modified versions (analogues) or derivatives thereof. A preferred modification is a modification that leads to a higher hydrophilicity, thus facilitating dissolution of the compound in an aqueous medium. Such modifications can be formation of ethers or esters on the phenols or substitution of the aromatic rings .
The present invention will be further elucidated in the following examples, which are given for illustration purposes only.
EXAMPLES EXAMPLE 1 Diagnosis of carcinoma in the bladder
The instillation solution was prepared as follows. 1 to 10 mM hypericin in absolute ethanol was diluted a thousand fold in a 1% plasma protein solution and sterile membrane filtered. 29 patients were included in the study. 22 presented with visible exophytic transitional cell carcinoma. One patient had interstitial cystitis. 7 patients had repeated positive urinary cytology, without detectable lesions at cystoscopy, sonography or urogram. Random biopsies previously performed without hypericin instillation had been negative in 2 of them.
Instillation time varied between 1 and 4 hours (1, 2, 3 and 4 hours) . At 2 to 24 hours after instillation, the patient were examined with white light cystoscopy, followed by blue light excitation. The system used for fluorescence diagnostics was developed by Storz company (D Light system) . It consists of a small light source, with a Xenon arc lamp with a corresponding band pass filter (380-450 nm) . By switching the foot pedal, the filter is placed or removed and blue or white light is produced, respectively. A conventional cystoscope is used for endoscopic examination, but the telescopes (0° and 30°) are provided with a long wavelength pass filter (>520 nm) to cut off the reflected blue excitation light without blocking the red fluorescence light. The telescopes are compatible with all Storz endoscopes .
Biopsies were performed from fluorescent positive and negative areas. The instillation did not provoke any side effects nor symptoms.
All papillary lesions showed red fluorescence. Effective bright light fluorescence was obtained with 50 ml of a 2μM (or higher) solution.
Instillation times of 1 hour did not provoke any visible red fluorescence and minimum of 2 hours is required. The brightest fluorescence could be observed after 3 to 4 hours. Fluorescence could be observed as early as 2 hours after instillation. The same intensity was observed after 12 to 16 hours, but was much reduced after 24 hours .
Carcinoma in situ could be correctly diagnosed in all of the patients with a suspicious cytology, without detectable tumor. 66 biopsies confirmed the presence of carcinoma in situ (Table 1) . 56 of those biopsies had shown red fluorescence at cystoscopy.
Table 1
Red fluorescence (+) and blue fluorescence (-) with regard to pathology
CIS = carcinoma in situ
NL = normal transitional cell epithelium NA = not applicable
The sensitivity is the chance that the test will give a positive result in case a pathology is present and is obtained by dividing the amount of exact positives by the total of exact positives and false negatives. The specificity is the chance that a malignancy is present when the test is positive and is obtained by dividing exact negative by the sum of exact negatives and false positives . EXAMPLE 2
Preparation of installation fluid
A concentrated preparation for installation was prepared as follows. Hypericin was dissolved in PEG 400 to a final concentration of 5 mM. The thus obtained solution is further diluted while stirring to 80 μM in an aqueous phosphate buffer, containing 4.2% mannitol (pH
7.2). Vials of 5 ml were filled, closed and sterilized at
121°C. Before the use the content of the vials can be added to 45 ml of an aqueous buffer of choice. The final concentration of the 50 ml installation fluid thus obtained is 8 μM.
The concentrate was kept in the dark at room temperature for 1 month before use. Its diagnostic potential was then found to be identical to preparations containing a plasma protein solution.

Claims

1. Use of hypericin or analogues or derivatives thereof for the preparation of a diagnostic or therapeutic composition for diagnosing or treating carcinoma.
2. Use as claimed in claim 1 wherein the carcinoma is carcinoma of hollow organs selected from the urinary tract, including the bladder, bronchi, peritoneal cavity, gastrointestinal tract, female genital tract.
3. Use as claimed in claim 1 or 2 wherein the carcinoma originates from urothelium.
4. Use as claimed in claim 3 wherein the carcinoma is carcinoma of the bladder.
5. Use as claimed in claim 4 wherein the carcinoma is carcinoma in situ of the bladder.
6. Use as claimed in claims 1-5, with the proviso that the derivatives are not hypericin polyacetate or hypericin polyphosphate.
7. Use as claimed in claims 1-5, with the proviso that hypericin is not used in combination with an energy donating chemical.
8. Diagnostic or therapeutic preparation for diagnosing or treating carcinoma, comprising a suitable amount of hypericin or analogues or derivatives thereof in a suitable carrier or excipient .
9. Diagnostic or therapeutic preparation as claimed in claim 8, which takes the form of an instillation fluid, an inhalable preparation or an oral administration form.
10. Instillation preparation for the diagnosis or therapy of carcinoma originating from the urothelium, comprising a suitable amount of hypericin or analogues or derivatives thereof in a suitable instillation fluid.
11. Instillation preparation as claimed in claim 10, wherein the suitable amount of hypericin is 1 to 10 μM.
12. Instillation preparation as claimed in claims 10 and 11, wherein the hypericin is adsorbed to a protein.
13. Instillation preparation as claimed in claim 12, wherein the protein is albumin or a plasma protein preparation.
14. Instillation preparation as claimed in claims 10-13 which is for use in diagnosing bladder carcinoma .
15. Instillation preparation as claimed in claims 10-13 which is for use in diagnosing carcinoma in situ.
16. Method for preparing an instillation preparation as claimed in claims 10-15, comprising the steps of : a) solubilisation of hypericin in an aqueous buffer to obtain a hypericin solution; and b) sterilisation of the solution thus obtained.
17. Method as claimed in claim 16, wherein the hypericin is solubilised by adsorption thereof to a protein, in particular albumin or a plasma protein preparation.
18. Method as claimed in claim 17, wherein the hypericin is solubilised by means of cyclodextrin or encapsulation in liposomes.
19. Method for preparing a diagnostic preparation as claimed in claims 8-15, comprising the steps of : a) dissolving hypericin in PEG 400; b) diluting the thus obtained solution with a buffer of bladder-compatible pH containing additives, such as mannitol, sorbitol or other poly-alcohols to obtain a stable concentrated preparation; and c) diluting the concentrated preparation prior to use in a buffer.
20. Method as claimed in claim 19, but instead of step c) comprising the step of lyofilisation of the preparation to obtain a dried preparation that can be reconstituted with water prior to use.
21. Method for diagnosing carcinoma, comprising contacting the site to be diagnosed for a suitable period of time with a suitable amount of a hypericin preparation, removing the preparation after lapse of the suitable period of time, illuminating the site with light of a suitable wavelength to excite the hypericin that has accumulated in the carcinoma to be diagnosed and detecting the fluorescence produced by the excited hypericin.
22. Method for diagnosing bladder cancer, comprising instilling in the bladder of a person to be diagnosed for a suitable period of time a suitable amount of an instillation preparation as claimed in claims 8-15, removing the instillation preparation after lapse of the suitable period of time, illuminating the bladder with light of a suitable wavelength to excite the hypericin that has accumulated in the carcinoma to be diagnosed and to detect fluorescence produced by the excited hypericin.
23. Method as claimed in claim 21, wherein the suitable period of time is at least 2 hours.
24. Method as claimed in claim 21 or 22, wherein the suitable amount is 30-70 ml, preferably 50 ml.
25. Method as claimed in claims 21-23, wherein the light is blue light.
26. Use of hypericin in the preparation of a therapeutical composition for the treatment of carcinoma, in particular carcinoma of hollow organs, more in particular carcinoma of the bladder.
EP00912602A 1999-03-11 2000-03-10 Means for diagnosing and treating carcinoma Withdrawn EP1162963A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP00912602A EP1162963A1 (en) 1999-03-11 2000-03-10 Means for diagnosing and treating carcinoma

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP99200747 1999-03-11
EP99200747A EP1040825A1 (en) 1999-03-11 1999-03-11 Means for diagnosing bladder carcinoma
EP00912602A EP1162963A1 (en) 1999-03-11 2000-03-10 Means for diagnosing and treating carcinoma
PCT/EP2000/002193 WO2000053170A1 (en) 1999-03-11 2000-03-10 Means for diagnosing and treating carcinoma

Publications (1)

Publication Number Publication Date
EP1162963A1 true EP1162963A1 (en) 2001-12-19

Family

ID=8239974

Family Applications (2)

Application Number Title Priority Date Filing Date
EP99200747A Withdrawn EP1040825A1 (en) 1999-03-11 1999-03-11 Means for diagnosing bladder carcinoma
EP00912602A Withdrawn EP1162963A1 (en) 1999-03-11 2000-03-10 Means for diagnosing and treating carcinoma

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP99200747A Withdrawn EP1040825A1 (en) 1999-03-11 1999-03-11 Means for diagnosing bladder carcinoma

Country Status (7)

Country Link
EP (2) EP1040825A1 (en)
JP (1) JP2002538201A (en)
KR (1) KR20020008124A (en)
AU (1) AU3429300A (en)
BR (1) BR0008914A (en)
WO (1) WO2000053170A1 (en)
ZA (1) ZA200107345B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100450523B1 (en) * 2002-03-13 2004-10-01 이종근 Shoehorn for pets
GB0723124D0 (en) * 2007-11-26 2008-01-02 Univ Leuven Kath Targeted radiotherapy
AT508680B1 (en) * 2009-05-19 2011-03-15 Onkotec Gmbh METHOD FOR THE QUALITATIVE AND / OR QUANTITATIVE DETERMINATION OF TUMOR CELLS
DE102014204138A1 (en) * 2014-03-06 2015-09-24 Briu Gmbh Pharmaceutical formulation, process for the preparation of the pharmaceutical formulation and infusion solution and their use as a medical device and / or as a medicament
US9629932B2 (en) * 2015-09-28 2017-04-25 Sanochemia Pharmazeutika Ag Photodynamic diagnosis, formulations usable as photosensitizers for this purpose, method for the production and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4228106A1 (en) * 1992-08-24 1994-03-03 Medac Klinische Spezialpraep Tumour diagnosis and treatment in organs, esp. urinary system - comprises admin. of gamma-amino-levulinic acid as photosensitiser, detection, and treatment by irradiation with neodymium-yttrium-aluminium-garnet laser
JPH08505054A (en) * 1992-12-23 1996-06-04 アイオア ステート ユニバーシティー リサーチ ファンデーション インコーポレーテッド Molecular flash
US6576784B1 (en) * 1993-05-27 2003-06-10 Yeda Research And Development Co. Ltd. Antiviral agents
JP3394566B2 (en) * 1993-07-16 2003-04-07 富士写真フイルム株式会社 Pharmaceutical composition for photochemotherapy of cancer
IT1275571B (en) * 1995-07-19 1997-08-07 Consiglio Nazionale Ricerche FLUOROGENIC SUBSTRATES SUSCEPTIBLE FOR PHOTOACTIVATION AFTER ENZYMATIC TRANSFORMATION SUITABLE FOR DIAGNOSIS AND PHOTODYNAMIC CANCER THERAPY
WO1997019705A1 (en) * 1995-12-01 1997-06-05 Elmaleh David R Stereoisomers of fatty acid analogs for diagnostic imaging

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0053170A1 *

Also Published As

Publication number Publication date
ZA200107345B (en) 2002-11-27
KR20020008124A (en) 2002-01-29
EP1040825A1 (en) 2000-10-04
AU3429300A (en) 2000-09-28
JP2002538201A (en) 2002-11-12
BR0008914A (en) 2002-01-29
WO2000053170A1 (en) 2000-09-14

Similar Documents

Publication Publication Date Title
US8410172B2 (en) Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
JP2004505040A (en) Composition
Datta et al. Quantitative studies of the kinetics of 5-aminolaevulinic acid-induced fluorescence in bladder transitional cell carcinoma
JPH04500770A (en) Methods for detecting and treating malignant and non-malignant lesions by photochemotherapy
Kabuto et al. Experimental and clinical study of detection of glioma at surgery using fluorescent imaging by a surgical microscope after fluorescein administration
AU2016372573B2 (en) Neoadjuvant therapy for bladder cancer
WO2000053170A1 (en) Means for diagnosing and treating carcinoma
RU2448745C2 (en) Method of treating superficial urinary bladder cancer
JP6800232B2 (en) Hypericin preparation for photodynamic diagnosis
EP3389716B1 (en) Method of photodynamic therapy (pdt) for bladder cancer
Banerjee et al. Bronchoscopic photodynamic diagnosis and therapy for lung cancer
Caro et al. Chromoendoscopy associated with endoscopic laryngeal surgery: a new technique for treating recurrent respiratory papillomatosis
RU2346657C1 (en) Method of treatment of superficial bladder cancer
RU2228775C1 (en) Photodynamic method for treating the cases of acute and chronic purulent maxillary sinusitis
Geavlete et al. Fluorescence cystoscopy
Spechler et al. Barrett's esophagus
RU2349311C1 (en) Application of naphthalene derivative as oncological disease treatment medicine
TWI635860B (en) Use of acridine derivatives for preparing pharmaceutical compositions for treating urothelial cancer
Lee Near-infrared fluorophores and cyclodextrin complex for improved cancer imaging and phototherapy
KAMASAKI et al. Fluorescence imaging of 5-aminolevulinic acid-induced protoporphyrin IX in tissues and cells using confocal laser scanning microscopy
RU2218570C2 (en) Fluorescent method for diagnosing neoplasms
Gould Tetracycline fluorescence in cancer detection
D'Hallewin et al. Fluorescence detection of flat transitional cell carcinoma after intravesical instillation of aminolevulinic acid
TI et al. A506 AGA ABSTRACTS GASTROENTEROLOGY, Vol. 108, No. 4

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011009

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20031001